Asset Details
Do you wish to reserve the book?
P499 Human papillomavirus detection in residual samples from STI tests in men who have sex with men
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
P499 Human papillomavirus detection in residual samples from STI tests in men who have sex with men
Do you wish to request the book?
P499 Human papillomavirus detection in residual samples from STI tests in men who have sex with men
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
P499 Human papillomavirus detection in residual samples from STI tests in men who have sex with men
2019
Overview
BackgroundAnorectal swab specimens, either alone, or pooled with first catch urine (FCU) and pharyngeal swab specimens, are used to test for STIs in MSM. The residual sample, after routine testing, may be used to monitor human papillomavirus (HPV) prevalence in this population, but the sensitivity of HPV detection in such specimens is unknown.MethodsMSM attending a UK sexual health clinic were consented to collect additional specimens to compare the detection of HPV in a dedicated swab, with detection in a residual anorectal and/or pooled specimen. All subjects provided 3 specimens: (i) anorectal swab (for chlamydia(CT)/gonorrhoea(GC) testing); (ii) pooled anorectal/pharyngeal/FCU specimen (for GC/CT); (iii) dedicated anorectal swab for HPV. Specimen (iii) and residual material from specimens (i) and (ii) were tested for type-specific HPV DNA (19 confirmed/possible high-risk (HR) genotypes and genotypes 6/11). HPV detection was by in-house multiplex PCR and Luminex-based genotyping assay.Results129 MSM were recruited; mean age 38.1 years; 24% were HIV-positive. 92/129 (71%) had type-specific HPV DNA detected in ≥1 specimen; 80/129 (62%) had HR-HPV. 70/123 participants (56.9%) with sufficient residual pooled specimen, and a dedicated HPV specimen had detectable HPV on both and 40 (32.5%) were HPV-negative on both; overall concordance 89% (95%CI 83,94). Prevalence in pooled samples was 4.1% (-1.9,10.0) higher than dedicated samples. 74/125 participants (59.2%) with sufficient residual anorectal specimen, and dedicated anorectal HPV specimen had detectable HPV on both and 36 (28.8%) were HPV-negative on both; overall concordance 88% (81,93). Prevalence in residual samples was 5.6% (-0.6,11.8) higher than dedicated samples.ConclusionResidual anorectal and pooled STI test specimens offer comparable sensitivity to anal HPV swab samples, which are typically used in prevalence studies. This supports use of residual samples to monitor HPV prevalence, as currently proposed in the UK to evaluate the impact of targeted MSM HPV vaccination.DisclosureNo significant relationships.
Publisher
BMJ Publishing Group LTD
Subject
